Clinical Trial: Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

Brief Summary: A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.

Detailed Summary: This is a prospective trial. Thirty-one patients with a primary pterygium of at least 2 mm in size and without any previous ocular surgery will be included. Outcome measures will include best corrected visual acuity, intraocular pressure, recurrence, and any sight threatening complications at two weeks, two months, and six months postoperatively.
Sponsor: Arrowhead Regional Medical Center

Current Primary Outcome: number of recurrent pterygia with postoperative bevacizumab [ Time Frame: 6 months ]

The number of recurrent pterygia with patients who received bevacizumab after pterygium excision was compared to the number of recurrences in those patients who only had pterygium excision.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Arrowhead Regional Medical Center

Dates:
Date Received: November 21, 2012
Date Started: April 2011
Date Completion:
Last Updated: November 26, 2012
Last Verified: November 2012